News on mass spectrometry technology and applications in genetics, genomics, and molecular diagnostics.
The company launched in November a survey-based test for screening patients for preterm birth risk that it plans to pair with a mass spectrometry-based assay.
One of a host of new methods used for diagnosis of and screening for COVID-19, there are still hurdles to widespread adoption of breath testing for the disease.
The companies have launched a 5,600 subject study to look at whether the test is able to improve outcomes and reduce costs among Anthem beneficiaries.
The organizations said the test will determine and monitor the status of patients using an innovative blood-based mass spectrometry laboratory assay.
The company also announced it has received approval from California to offer the test, which it launched in October as a lab-developed test, in that state.
